San Diego—In younger patients with mantle cell lymphoma (MCL) who have received an autologous hematopoietic cell transplant (auto-HCT) after an induction regimen, rituximab maintenance significantly improves outcomes including overall survival (OS), according to the multicenter Phase III LyMa trial.
“Rituximab [Rituxan, Genentech] maintenance has already been shown to prolong OS in elderly MCL patients after R-CHOP [rituximab plus cyclophosphamide, doxorubicin, vincristine,